1. Home
  2. KALV vs QNST Comparison

KALV vs QNST Comparison

Compare KALV & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$17.04

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Logo QuinStreet Inc.

QNST

QuinStreet Inc.

HOLD

Current Price

$11.49

Market Cap

679.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
QNST
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
679.9M
IPO Year
2014
2009

Fundamental Metrics

Financial Performance
Metric
KALV
QNST
Price
$17.04
$11.49
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$30.00
$24.75
AVG Volume (30 Days)
761.7K
734.4K
Earning Date
05-09-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.94
Revenue
$50,000,000.00
$282,140,000.00
Revenue This Year
N/A
$18.59
Revenue Next Year
N/A
$14.96
P/E Ratio
N/A
$12.80
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$10.29
52 Week High
$19.00
$19.53

Technical Indicators

Market Signals
Indicator
KALV
QNST
Relative Strength Index (RSI) 55.56 43.40
Support Level $14.59 $10.54
Resistance Level $17.30 $15.52
Average True Range (ATR) 1.10 0.50
MACD -0.05 0.05
Stochastic Oscillator 53.88 16.42

Price Performance

Historical Comparison
KALV
QNST

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About QNST QuinStreet Inc.

QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.

Share on Social Networks: